Professor of Radiation Oncology, University Tex Houston
Radiology
Dr. Deborah A. Kuban, MD
|
|
Give Review
Deborah Kuban is an expert in the field of Radiology. She went to Eastern Virginia Medical School. She received 3 awards: "America's Top Doctors", "Top Doctors:SE Texas" and "America's Top Doctors for Cancer". Deborah A. Kuban is a published doctor and has 99 publications published. The lastest was: 'Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing.' Deborah Kuban accepts all Medicare patients.
Publications
- Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing.
- The Relationship Between Illness Uncertainty, Anxiety, Fear of Progression, and Quality of Life in Men With Favorable Risk Prostate Cancer Undergoing Active Surveillance.
- Establishing high-quality prostate brachytherapy using a phantom simulator training program.
- Physician Variation in Management of Low-Risk Prostate Cancer: A Population-Based Cohort Study.
- Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic.
- Current Clinical Presentation and Treatment of Localized Prostate Cancer in the United States.
- The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer.
- Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.
- Positive FDG-PET/CT Scans of a Residual Seminoma After Chemotherapy and Radiotherapy: Case Report and Review of the Literature.
- 'It's not like you just had a heart attack': decision-making about active surveillance by men with localized prostate cancer.
- Quality of Life and Toxicity From Passively Scattered and Spot-Scanning Proton Beam Therapy for Localized Prostate Cancer.
- Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study.
- Declining use of brachytherapy for the treatment of prostate cancer.
- Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients.
- A Fully Automated Method for CT-on-Rails-Guided Online Adaptive Planning for Prostate Cancer Intensity Modulated Radiation Therapy.
- Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation.
- Multi-institutional Prospective Evaluation of Bowel Quality of Life After Prostate External Beam Radiation Therapy Identifies Patient and Treatment Factors Associated ...
- Outcomes in stage I testicular seminoma: A population-based study of 9193 patients.
- Sunitinib Plus Androgen Deprivation and Radiation Therapy for Patients With Localized High-Risk Prostate Cancer: Results From a Multi-institutional Phase 1 Study.
- PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation The...
- Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate c...
- Is Androgen Deprivation Therapy Necessary in All Intermediate-Risk Prostate Cancer Patients Treated in the Dose Escalation Era?
- A Comprehensive Comparison of IMRT and VMAT Plan Quality for Prostate Cancer Treatment.
- Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease?
- Knife or needles? A cohort analysis of outcomes after radical prostatectomy or brachytherapy for men with low- or intermediate-risk adenocarcinoma of the prostate.
- Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy.
- Prediction of erectile function following treatment for prostate cancer.
- Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy.
- Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?
- Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials.
- Toxicity Associated With Postoperative Radiation Therapy for Prostate Cancer.
- Toward a real-time in vivo dosimetry system using plastic scintillation detectors.
- A volumetric trend analysis of the prostate and seminal vesicles during a course of intensity-modulated radiation therapy.
- Localized prostate cancer: the battle of treatment options enters the larger arena.
- Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience.
- Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy.
- Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer.
- Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy.
- A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.
- Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era?
- Performance evaluation of automatic anatomy segmentation algorithm on repeat or four-dimensional computed tomography images using deformable image registration method.
- Quantification of prostate and seminal vesicle interfraction variation during IMRT.
- Daily bone alignment with limited repeat CT correction rivals daily ultrasound alignment for prostate radiotherapy.
- Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.
- Treatment-planning study of prostate cancer intensity-modulated radiotherapy with a Varian Clinac operated without a flattening filter.
- Changes in the pelvic anatomy after an IMRT treatment fraction of prostate cancer.
- Uncertainty of calculated risk estimates for secondary malignancies after radiotherapy.
- An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for ...
- Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
- The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome.
- Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
- Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment.
- Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United St...
- Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
- Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy.
- Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy a...
- First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival.
- Comparison of biochemical failure definitions for permanent prostate brachytherapy.
- Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer.
- Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups.
- PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
- Does postoperative adjuvant radiotherapy reduce biochemical progression after radical prostatectomy?
- Comparison of treatment volumes and techniques in prostate cancer radiation therapy.
- Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer?
- Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy.
- The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy.
- Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy.
- Ultrasound-based localization.
- Defining recurrence after radiation for prostate cancer.
- Symptomatic local recurrence of prostate carcinoma after radiation therapy.
- Implementation and validation of a three-dimensional deformable registration algorithm for targeted prostate cancer radiotherapy.
- Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutiona...
- Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.
- Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer.
- High-dose intensity modulated radiation therapy for prostate cancer.
- PSA after radiation for prostate cancer.
- Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
- The delivery of IMRT with a single physical modulator for multiple fields: a feasibility study for paranasal sinus cancer.
- Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.
- Utility of the percentage of positive prostate biopsies in predicting PSA outcome after radiotherapy for patients with clinically localized prostate cancer.
- Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy.
- Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancer.
- Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study.
- Use of portal images and BAT ultrasonography to measure setup error and organ motion for prostate IMRT: implications for treatment margins.
- Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate.
- Experience of ultrasound-based daily prostate localization.
- Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma.
- Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer.
- Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial.
- Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.
- Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer.
- Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer.
- Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.
- Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation.
- Intrafraction prostate motion during IMRT for prostate cancer.
- Dosimetric effects of weight loss or gain during volumetric modulated arc therapy and intensity-modulated radiation therapy for prostate cancer.
- Prospective peer review quality assurance for outpatient radiation therapy.
- Local recurrence map to guide target volume delineation after radical prostatectomy.
Schools
Medical College Of Georgia School Of Medicine
Eastern Virginia Med School
Doctors Specialties
- Radiation Oncology
- Radiology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
Education
-
Eastern Virginia Medical School -
Medical College of Georgia School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1376648188 | |
| NPPES Provider LastName | KUBAN | |
| NPPES Provider FirstName | DEBORAH | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 74.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1376648188 |
| Last Name Of The Provider | KUBAN |
| First Name Of The Provider | DEBORAH |
| View All |
Similar Doctors
|
|
Dr. John P. Ricks III, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Le E. Richey Jr., MD |
|
|
Dr. Susan L. McGovern, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vasanthi D. Rao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David I. Rosenthal, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Theodore K. Yang, MD |
|
|
Dr. Barry D. Toombs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew T. Ballo, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Neelofur Ahmad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paige M. Green, MD |
|
|
Dr. Luis Delclos, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Gary R. Leach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Herbert M. Loyd, MD |
|
|
Dr. Miguel G. Fabrega, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John M. Phillips Jr., MD |
|
|
Dr. Joe B. Wilson, MD |
|
|
Dr. Steven S. Gerguis, MD |
|
|
Dr. Megan E. Speer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Sireesha Yedururi, MB
This Doctor is OpenDoctor Recommended.
|